Edwards Lifesciences Corporation $EW Shares Sold by OLD National Bancorp IN

by · The Cerbat Gem

OLD National Bancorp IN trimmed its position in Edwards Lifesciences Corporation (NYSE:EW – Free Report) by 69.4% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 58,421 shares of the medical research company’s stock after selling 132,226 shares during the quarter. OLD National Bancorp IN’s holdings in Edwards Lifesciences were worth $4,543,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Norges Bank purchased a new position in Edwards Lifesciences in the second quarter valued at approximately $580,640,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its position in shares of Edwards Lifesciences by 111.2% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company’s stock worth $714,006,000 after acquiring an additional 4,805,819 shares in the last quarter. Marshall Wace LLP raised its stake in shares of Edwards Lifesciences by 127.5% in the 2nd quarter. Marshall Wace LLP now owns 6,895,579 shares of the medical research company’s stock valued at $539,303,000 after acquiring an additional 3,864,908 shares during the period. Jennison Associates LLC lifted its holdings in shares of Edwards Lifesciences by 15.7% during the 2nd quarter. Jennison Associates LLC now owns 11,670,991 shares of the medical research company’s stock valued at $912,788,000 after acquiring an additional 1,584,958 shares in the last quarter. Finally, Holocene Advisors LP boosted its position in Edwards Lifesciences by 35.2% during the 2nd quarter. Holocene Advisors LP now owns 4,703,977 shares of the medical research company’s stock worth $367,898,000 after purchasing an additional 1,223,460 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Price Performance

EW opened at $86.21 on Wednesday. The company has a market capitalization of $50.03 billion, a P/E ratio of 37.16, a PEG ratio of 3.89 and a beta of 0.97. The company has a 50-day moving average of $83.06 and a 200-day moving average of $79.41. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00. Edwards Lifesciences Corporation has a 1-year low of $65.94 and a 1-year high of $87.89.

Edwards Lifesciences (NYSE:EW – Get Free Report) last posted its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. The business had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The company’s revenue for the quarter was up 14.7% compared to the same quarter last year. During the same period last year, the firm earned $0.67 earnings per share. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. Equities analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 11,386 shares of the firm’s stock in a transaction on Friday, December 12th. The stock was sold at an average price of $83.76, for a total transaction of $953,691.36. Following the transaction, the vice president directly owned 38,970 shares in the company, valued at $3,264,127.20. This trade represents a 22.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 1,020 shares of the business’s stock in a transaction on Monday, November 10th. The shares were sold at an average price of $82.55, for a total transaction of $84,201.00. Following the sale, the vice president owned 22,002 shares of the company’s stock, valued at approximately $1,816,265.10. The trade was a 4.43% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 45,465 shares of company stock worth $3,804,610. 0.34% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. Royal Bank Of Canada raised their price objective on Edwards Lifesciences from $95.00 to $100.00 and gave the company an “outperform” rating in a research report on Friday, December 5th. UBS Group set a $92.00 target price on Edwards Lifesciences in a report on Friday, December 5th. The Goldman Sachs Group set a $104.00 price objective on shares of Edwards Lifesciences and gave the company a “buy” rating in a research report on Friday, October 31st. Wells Fargo & Company set a $100.00 target price on shares of Edwards Lifesciences in a research report on Thursday, December 18th. Finally, Barclays reaffirmed an “overweight” rating and set a $103.00 price target (up from $99.00) on shares of Edwards Lifesciences in a report on Monday, December 8th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Edwards Lifesciences currently has an average rating of “Moderate Buy” and a consensus target price of $93.95.

View Our Latest Research Report on EW

Edwards Lifesciences Company Profile

(Free Report)

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

See Also

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW – Free Report).